<DOC>
	<DOCNO>NCT02994732</DOCNO>
	<brief_summary>The primary objective study characterize metabolic disposition , pharmacokinetics ( PK ) , rout elimination [ 14C ] ‑labeled BVD‑523 administration single , oral dose healthy male subject . The secondary objective study evaluate safety tolerability single oral dose [ 14C ] ‑labeled BVD‑523 healthy male subject .</brief_summary>
	<brief_title>Absorption , Metabolism Excretion ( AME ) Single Dose Radiolabeled BVD-523 Volunteers</brief_title>
	<detailed_description />
	<criteria>Males , 18 65 year age , inclusive , Screening Have body mass index range 18.5 32.0 kg/m2 , inclusive , Screening In good health , determine clinically significant finding medical history , 12‑lead ECG , vital sign measurement Screening Checkin PE finding Checkin determine Investigator ( designee ) Clinical laboratory evaluation ( include clinical chemistry panel [ fast least 8 hour ] , hematology/complete blood count [ CBC ] , urinalysis [ UA ] within reference range test laboratory Screening Check‑in , unless deem clinically significant Investigator ( designee ) Negative test select drug abuse cotinine Screening ( include alcohol ) Check‑in ( include alcohol ) Negative hepatitis panel ( include hepatitis B surface antigen hepatitis C virus antibody ) negative human immunodeficiency virus ( HIV ) antibody screen Screening Males surgically sterile least 90 day ( confirm document azoospermia ) , sexuallyactive female partner childbearing potential , agree use contraception detail Section 6.3.3 Checkin 90 day follow Discharge Males must willing refrain sperm donation Checkin 90 day day dose Able comprehend willing sign ICF A minimum 1 bowel movement per day . Significant history clinical manifestation metabolic , allergic , infectious , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator [ designee ] ) prior Check‑in History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ( designee ) prior Check‑in History stomach intestinal surgery resection could alter absorption excretion orally administer drug prior Check‑in except appendectomy , hernia repair allow associate ; History Gilbert 's Syndrome History presence abnormal ECG , Investigator 's ( designee 's ) opinion , clinically significant History alcoholism drug addiction within 1 year prior Check‑in History nicotine use within 6 month prior Checkin positive cotinine Screening Checkin Participation 1 radiolabeled investigational study drug trial within 12 month prior Checkin . The previous radiolabeled study drug must receive 6 month prior Check‑in study total exposure study previous study within recommend level consider safe , per United States ( US ) Title 21 Code Federal Regulations ( CFR ) 361.1 ( eg , less 3,000 mrem whole body annual exposure ) Exposure significant radiation ( eg , serial x‑ray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) within 12 month prior Check‑in Use drug substance know strong inhibitor strong inducer CYP3A enzyme within 30 day prior study drug administration , unless otherwise state , throughout study Participation investigational study drug trial receipt investigational study drug occur within 5 halflives ( know ) 30 day prior Check‑in , whichever long Use prescription medications/products within 14 day prior Check‑in , unless deem acceptable Investigator ( designee ) Use overthecounter , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Check‑in , unless deem acceptable Investigator ( designee ) Poor peripheral venous access prior Check‑in Donation whole blood 56 day prior Screening Discharge , inclusive , plasma 30 day prior Screening Discharge , inclusive Receipt blood product within 2 month prior Check‑in Any acute chronic condition , opinion Investigator ( designee ) , would limit subject 's ability complete participate clinical study Any unspecified reason , opinion Investigator ( designee ) Sponsor , make subject unsuitable enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>